Top Pharmaceutical Companies in Singapore (53)
The Schwabe Group comprises several different affiliated companies in the pharmaceutical and health industry. All of the companies within the Schwabe Group focus on plants as the basis for developing pharmaceuticals and health products. The parent company of the Schwabe Group, which is now Dr. Willmar Schwabe GmbH & Co. KG, is one of the oldest pharmaceutical manufacturers in Europe...
Biomed Global is a leading total solution provider in the biomedical and life sciences industry, operating across Southeast Asia. The company provides a holistic range of innovative medical solutions and cutting-edge biomedical technologies spanning research, development, and clinical applications. Its mission is to advance healthcare standards and facilitate medical breakthroughs by bringing together leading-edge medical solutions and expert support to...
Princeton Biopartners is a best-in-class provider of integrated consulting solutions to the life sciences sector. Our mission is to improve the evidence base, accessibility, and impact of biomedical innovations through strategic advisory, software, and our venture fund. We pride ourselves on establishing long-term client relationships and are dedicated to addressing pain points via integrated and transformative projects. Setting new standards...
Kyberlife's technology arm holds the first open marketplace in Asia with an easy-to-use platform that hosts healthcare vendors, life-science companies & manufacturers globally. Kyberlife also has a distribution arm that facilitates licensed distribution of life-science/pharmaceutical/medical products, Instruments, equipment to the SEA region. Our vision is to provide for the millions of researchers in Asia, SEA & Australasia to shop for...
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.
Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.
Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.
Raffles Pharmatech is a leading provider of advanced chemical development and manufacturing services. We specialize in delivering high-quality intermediates RSMs, APIs and custom chemicals to support the pharmaceutical and specialty chemicals industries from concept through to commercialization. With state-of-the-art facilities and a commitment to innovation, Raffles Pharmatech partners with companies globally. Our expert team of ~300 dedicated staff, combined with our...
As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to...
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with...
Roche's Top Stability & Growth Strengths
Strong Market Position & Advantage: Roche is the global leader in in‑vitro diagnostics and remains a top‑tier biopharma with a significant oncology footprint. The dual Pharmaceuticals–Diagnostics model is a strategic differentiator at scale.
Strong Revenue Growth: Group sales rose 7% at constant exchange rates in 2025 and 6% at CER in Q1 2026, with both divisions contributing. Guidance for 2026 indicates continued mid–single‑digit CER growth.
Profitability: Profitability improved in 2025 alongside sales, with higher IFRS net income and core EPS growth. Management pointed to capacity to keep investing while rewarding shareholders.
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts,...
Alcon's Top Stability & Growth Strengths
Strong Market Position & Advantage: The business is positioned as a global leader in eye care with meaningful share in contact lenses and one of the largest installed bases in ophthalmic surgical equipment, supporting durable demand across geographies. Scale across Vision Care and Surgical also supports recurring revenue via consumables tied to the installed base.
Resilient & Sustainable Growth: Revenue is described as growing year over year with guidance calling for continued mid-single-digit constant-currency sales growth into 2026, supported by steady demand for essential procedures like cataract surgery. The company is also positioned to outpace broader eye-care market growth expectations per the provided outlook.
Healthy Cash Flow: Cash generation is described as strong, with operating cash flow and free cash flow at sizable levels that support ongoing investment and shareholder returns. This cash profile provides resilience against near-term cost headwinds and funding for launches and efficiency programs.
Procter & Gamble Company is an American multi-national consumer goods corporation. P&G was founded over 180 years ago as a soap and candle company. Today, we’re the world’s largest consumer goods company and home to iconic, trusted brands, including Always®, Charmin®, Braun®, Fairy®, Febreze®, Gillette®, Head & Shoulders®, Oral B®, Pantene®, Pampers®, Tide®, and Vicks®. The design, development, growth and success...
Procter & Gamble's Top Stability & Growth Strengths
Strong Market Position & Advantage: P&G is consistently characterized as the clear industry leader with dominant positions across core categories, anchored by flagship brands like Tide, Pampers, Gillette, Crest, and Oral‑B. Multiple sources in the provided materials frame it as leading peers across home care, baby/feminine, grooming, and oral care.
Innovation-Driven Growth: The company is repeatedly recognized for leadership in product innovation and is advancing new formats and data‑driven operations to sustain momentum. References cite top‑ranked innovation in household products for multiple consecutive years and highlight launches such as new detergent formats.
Resilient & Sustainable Growth: Recent updates indicate a return to positive unit volumes with modest organic sales and EPS increases, alongside reaffirmed low single‑digit growth guidance. Dividend increases and ongoing cash returns are emphasized as continuing, underscoring a steady, durable profile.
A science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how...
GSK's Top Stability & Growth Strengths
Strong Market Position & Advantage: GSK is positioned as a top-tier global biopharmaceutical company by revenue while showing category leadership in vaccines and HIV, anchored by franchises such as Shingrix and ViiV’s portfolio. Its consistent top-10/12 standing and segment leadership in vaccines, respiratory, and HIV support a stable competitive footing.
Resilient & Sustainable Growth: Revenue and earnings momentum are supported by broad-based growth across Specialty Medicines and continued contributions from Vaccines, alongside reaffirmed multi-year sales ambitions. Guidance for continued turnover and profit expansion indicates an expectation of ongoing, steadier growth rather than a one-off spike.
Healthy Cash Flow: Operating cash generation is described as strong and is being used to fund R&D investment and shareholder returns such as dividends and buybacks. This cash profile supports resilience through investment cycles and potential volatility in specific product areas.
At Lonza, we enable A Healthier World by supporting our healthcare customers on the path to commercialization. Our community of 16,000 talented employees work across a global network of more than 30 sites to deliver for our customers across the pharma, biotech and nutrition markets.
BCD is a leading process engineering solutions company, delivering high-purity process solutions to pharmaceutical, biotech, food and beverage, and chemical customers worldwide since 1983.
WonderLab is a non-profit organization providing pediatric physical, occupational, and speech therapy services.
Edwards Lifesciences (NYSE: EW), is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. We thrive on discovery and expanding the boundaries of medical technology, serving patients in 100+ countries, with the help of our employees in areas including Clinical Affairs, Quality Engineering, Research & Development, Regulatory Affairs, Sales &...
Edwards Lifesciences's Top Stability & Growth Strengths
Strong Market Position & Advantage: Edwards is broadly characterized as the TAVR category leader anchored by the SAPIEN portfolio, and its first-to-approval EVOQUE tricuspid replacement reinforces leadership across structural heart. Industry trackers and company updates point to durable share and breadth across aortic, mitral, and tricuspid therapies.
Strong Revenue Growth: Recent results show double-digit top-line expansion and successive raises to the 2026 sales outlook, driven by steady TAVR demand and rapid TMTT growth. Management commentary emphasizes continued momentum with a consistent long-term growth ambition.
Innovation-Driven Growth: First-to-approval EVOQUE in tricuspid replacement, rapid uptake of PASCAL in mitral repair, and extensive long-term SAPIEN evidence position the portfolio for further adoption. Regulatory and policy catalysts, including a pending CMS TAVR coverage reconsideration and accumulating durability data, may expand access.
Omya is a leading global producer of industrial minerals, primarily fillers and pigments derived from calcium carbonate and dolomite, and a worldwide distributor of specialty materials. The company operates across diverse sectors, including construction, polymers, pulp and paper, agriculture, and life sciences. It provides high-purity minerals and specialty ingredients designed to improve process efficiency and performance for customers in over...
Vantive is a standalone vital organ therapy company dedicated to extending lives and expanding possibilities for patients and care teams globally. Building on a 70-year legacy in kidney care, Vantive provides innovative therapies, digital solutions, and advanced services for dialysis and critical care. The company operates in over 100 countries, focusing on improving outcomes for millions of patients through its...
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
Novartis's Top Stability & Growth Strengths
Strong Revenue Growth: Novartis shows multi-year sales expansion, with full-year results indicating continued top-line growth driven by priority brands across several therapeutic areas.
Profitability: Margins and operating income are described as strengthening, with core operating margin reaching about 40% alongside year-over-year core operating income growth.
Innovation-Driven Growth: Growth is supported by scaling priority brands and a deep pipeline with multiple high-value assets, alongside business development to add late- and mid-stage programs.
MMR Consulting Inc. and its dedicated team of experienced consultants are committed to delivering high quality, robust solutions for the Pharmaceutical and Biotechnology industries. Our expertise includes Engineering (Process, Automation, Facilities), Capital Project Management of large/complex projects and programs, Commissioning Qualification Validation, and GMP Compliance services.
Wellesta Holdings Pte Ltd is a company that is headquartered in Singapore, set up to support companies in the Healthcare sector to provide marketing and commercial support in South East Asia and India. It will act as a representative for companies that are not present in this geography and would like to sell/ market their products in the region. We...
